汇宇制药(688553.SH)：公司产品获得境外上市许可

Core Viewpoint - The company has received marketing approvals for its injectable drugs in the Netherlands and Saudi Arabia, enhancing its international market presence and product pipeline [1] Group 1: Product Approvals - The company's subsidiary Seacross Pharma (Europe) Ltd. and Seacross Pharmaceuticals Ltd. have recently obtained marketing licenses from the Dutch Medicines and Health Products Regulatory Authority and the Saudi Food and Drug Authority for injectable Parecoxib Sodium [1] - Injectable Parecoxib Sodium is indicated for the treatment of short-term postoperative pain in adults, which expands the company's product offerings in the pain management segment [1] - Injectable Pemetrexed Disodium, another product, is approved for use in chemotherapy for unresectable malignant pleural mesothelioma and locally advanced or metastatic lung cancer, enhancing the company's oncology portfolio [1] Group 2: Market Expansion - The approvals for injectable Parecoxib Sodium and injectable Pemetrexed Disodium are expected to enrich the company's international product pipeline, improve its brand image, and facilitate the continuous expansion of its international business [1]